Bolt Biotherapeutics, Inc. Share-based Payment Arrangement, Expense
Bolt Biotherapeutics, Inc. (BOLT) reported Share-based Payment Arrangement, Expense of $552.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $552.00K, a 11.68% decline year-over-year.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $545.00K, a 23.13% decline year-over-year.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.04M, a 11.93% decline year-over-year.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $407.00K, a 62.93% decline year-over-year.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $2.78M, a 62.44% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $7.41M, a 19.69% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $9.22M, a 3.69% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $9.58M, a 12.66% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $552.00K 10-Q · filed 2026-08-11 | $1.10M 10-Q · filed 2026-08-11 | $2.14M derived: sum of 3 quarters · filed 2026-08-11 | $2.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $545.00K 10-Q · filed 2026-05-12 | $1.59M derived: sum of 2 quarters · filed 2026-05-12 | $1.99M derived: sum of 3 quarters · filed 2026-05-12 | $2.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.45M derived: sum of 2 quarters · filed 2026-03-12 | $2.07M derived: sum of 3 quarters · filed 2026-08-11 | $2.78M 10-K · filed 2026-03-12 |
| 2025-09-30 | $407.00K 10-Q · filed 2025-11-12 | $1.03M derived: sum of 2 quarters · filed 2026-08-11 | $1.74M 10-Q · filed 2025-11-12 | $2.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $625.00K 10-Q · filed 2026-08-11 | $1.33M 10-Q · filed 2026-08-11 | $2.52M derived: sum of 3 quarters · filed 2026-08-11 | $3.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $709.00K 10-Q · filed 2026-05-12 | $1.89M derived: sum of 2 quarters · filed 2026-05-12 | $2.99M derived: sum of 3 quarters · filed 2026-05-12 | $5.81M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.28M derived: sum of 2 quarters · filed 2026-03-12 | $5.11M derived: sum of 3 quarters · filed 2026-03-12 | $7.41M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.10M 10-Q · filed 2025-11-12 | $3.92M derived: sum of 2 quarters · filed 2025-11-12 | $6.22M 10-Q · filed 2025-11-12 | $8.29M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.83M 10-Q · filed 2025-08-14 | $5.13M 10-Q · filed 2025-08-14 | $7.20M derived: sum of 3 quarters · filed 2025-08-14 | $9.52M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-12 | $4.37M derived: sum of 2 quarters · filed 2025-05-12 | $6.70M derived: sum of 3 quarters · filed 2025-05-12 | $9.05M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.40M derived: sum of 2 quarters · filed 2025-03-24 | $6.75M derived: sum of 3 quarters · filed 2025-03-24 | $9.22M 10-K · filed 2025-03-24 |
| 2023-09-30 | $2.33M 10-Q · filed 2024-11-12 | $4.68M derived: sum of 2 quarters · filed 2024-11-12 | $7.16M 10-Q · filed 2024-11-12 | $9.28M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.35M 10-Q · filed 2024-08-13 | $4.83M 10-Q · filed 2024-08-13 | $6.95M derived: sum of 3 quarters · filed 2024-08-13 | $9.09M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.48M 10-Q · filed 2024-05-14 | $4.60M derived: sum of 2 quarters · filed 2024-05-14 | $6.74M derived: sum of 3 quarters · filed 2024-05-14 | $9.13M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.27M derived: sum of 2 quarters · filed 2024-03-21 | $6.66M derived: sum of 3 quarters · filed 2024-03-21 | $9.58M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.14M 10-Q · filed 2023-11-09 | $4.53M derived: sum of 2 quarters · filed 2023-11-09 | $7.45M 10-Q · filed 2023-11-09 | $9.60M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.39M 10-Q · filed 2023-08-07 | $5.31M 10-Q · filed 2023-08-07 | $7.45M derived: sum of 3 quarters · filed 2023-08-07 | $9.68M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $2.92M 10-Q · filed 2023-05-11 | $5.06M derived: sum of 2 quarters · filed 2023-05-11 | $7.29M derived: sum of 3 quarters · filed 2023-05-11 | $9.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.37M derived: sum of 2 quarters · filed 2023-03-29 | $6.39M derived: sum of 3 quarters · filed 2023-03-29 | $8.50M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.23M 10-Q · filed 2022-11-10 | $4.25M derived: sum of 2 quarters · filed 2022-11-10 | $6.36M 10-Q · filed 2022-11-10 | $6.93M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.02M 10-Q · filed 2022-08-10 | $4.13M 10-Q · filed 2022-08-10 | $4.70M derived: sum of 3 quarters · filed 2022-08-10 | $5.10M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.11M 10-Q · filed 2022-05-12 | $2.68M derived: sum of 2 quarters · filed 2022-05-12 | $3.08M derived: sum of 3 quarters · filed 2022-05-12 | $3.30M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $972.00K derived: sum of 2 quarters · filed 2022-03-30 | $1.20M derived: sum of 3 quarters · filed 2022-03-30 | $1.42M 10-K · filed 2022-03-30 |
| 2020-09-30 | $403.00K 10-Q · filed 2021-11-09 | $626.00K derived: sum of 2 quarters · filed 2021-11-09 | $851.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $223.00K 10-Q · filed 2021-08-12 | $448.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $225.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |